EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer

K Fanucci, A Giordano, T Erick, S M Tolaney, S Sammons

ESMO Open · 2024-12 · 9 (12) · 103997

DOI: 10.1016/j.esmoop.2024.103997 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ESMO Open, 2024-12. Verfasst von K Fanucci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Class I Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesFemaleHumansErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneSignal Transduction

Stichwörter der Autor:innen

AKT mutationHR+ metastatic breast cancerPIK3CA mutationPTEN alterationtoxicity

Substanzen

Class I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneTOR Serine-Threonine KinasesERBB2 protein, humanMTOR protein, humanPIK3CA protein, human

Autor:innen und Institutionen

  • Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: https://twitter.com/Kristina…
  • Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: https://twitter.com/antgiord…
  • Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA. Electronic address: https://twitter.com/DrTimothyErick.
  • Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: https://twitter.com/stolaney…
  • Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: sarahl_sammons@dfci.harvard.…

Zitieren

APA

Fanucci, K., Giordano, A., Erick, T., Tolaney, S. M., & Sammons, S. (2024). Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. ESMO Open, 9(12), 103997. https://doi.org/10.1016/j.esmoop.2024.103997

Vancouver

Fanucci K, Giordano A, Erick T, Tolaney SM, Sammons S. Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer. ESMO Open. 2024;9(12):103997. doi:10.1016/j.esmoop.2024.103997

BibTeX
@article{Fanucci2024,
  author = {Fanucci, K and Giordano, A and Erick, T and Tolaney, S M and Sammons, S},
  title = {Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer},
  journal = {ESMO Open},
  year = {2024},
  volume = {9},
  number = {12},
  pages = {103997},
  doi = {10.1016/j.esmoop.2024.103997}
}
Kostenlos starten →